Each year, millions of patients contract infectious diseases while in hospital. These HAIs not only lengthen hospital stays and utilize resources, such as ...
Self-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs), according to research pre...
National Dental Centre Singapore’s research arm, the National Dental Research Institute Singapore (NDRIS) has established an international collaborat...
Analyses Show Oral Bridging Maintains Virologic Suppression When Subcutaneous Lenacapavir Doses are Missed – Gilead Sciences, Inc. (Na...
IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") announced the execution of a Research Grant Agreement with Karolinska Unive...
Optogenetic platform will be combined with AI at Integrated Biosciences to identify candidate anti-aging drugs Scientists demonstrate that cells make an i...
Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the planned init...
From rare disease to oncology and beyond, this unique partnership is designed to deliver increased profits to clients, enable more advanced and secure data...
Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce the results of a recent sc...
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat...
Versanis' lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling. Bimagrumab...
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in p...
FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter...
Under the terms for the line of credit, IGC can draw up to $1 million within a 30-day period. The interest rate for a draw is 1% plus the rate paid on cert...
© 2024 Biopharma Boardroom. All Rights Reserved.
